Abstract:Abstract Estrogen and progesterone signaling together drive hormone-receptor positive breast cancer growth and progression. However, there have been limited studies on the independent role that progesterone and its receptor, the progesterone receptor (PR), play in the development of breast cancer. Studies in the Hagan lab have shown that progesterone signaling promotes mammary tumor growth and changes the immune landscape of the mammary gland towards immunosuppression. Regulatory T-cells (Tregs) are immune cells known to promote immunosuppression in the tumor microenvironment. The data from our lab shows that among hormone receptor positive breast cancers, higher levels of PR expression correlates to higher levels of Tregs in the tumor microenvironment. To determine if progesterone signaling increases the number of Tregs in the tumor-bearing mammary gland, we used a syngeneic orthotopic murine tumor model, E0771 cells, engineered to express mouse PR or control empty vector. Mice were treated with progesterone or placebo for 7 days before implantation of the modified E0771 cells. The results of this study show that progesterone promoted tumor growth, and flow cytometry analysis at tumor endpoint showed that PR-positive tumors treated with progesterone harbored more Tregs than mice treated with placebo. Additionally, initial studies using flow cytometry and RNA-seq indicate increased Treg activity following progesterone treatment in PR+ tumor-bearing mice. As progesterone treatment promoted tumor growth and Treg recruitment in progesterone receptor-positive tumors, these data imply that progesterone treatment may promote the release of secreted factors impacting the immune cells in the mammary microenvironment. To determine if progesterone treatment results in cytokine or chemokine changes that may affect Treg recruitment, cytokine arrays and enzyme-linked immunosorbent assays (ELISAs) were performed using cell culture supernatant from murine mammary tumor cells expressing progesterone receptor (E0771-PR) treated with progesterone (0-72 hours). E0771-PR cells treated with progesterone showed higher levels of cytokines and chemokines that have been linked to Treg recruitment and differentiation, such as MCSF. Our findings demonstrate that progesterone signaling promotes an immune suppressed microenvironment in the mammary gland through an increase in Tregs. This evidence provides rationale to investigate the use of anti-progestins as a mechanism to overcome the immune-cold tumor microenvironment seen in progesterone receptor positive breast tumors. Citation Format: Eilidh I. Chowanec, Lauryn R. Werner, Christy R. Hagan. Progesterone impacts regulatory T cell activity to promote immunosuppression in the mammary gland [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3971.

Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression

Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge

Integrity of the LXXLL Motif in Stat6 is Required for the Inhibition of Breast Cancer Cell Growth and Enhancement of Differentiation in the Context of Progesterone

Prolactin Receptor Expression and Breast Cancer: Relationships with Tumor Characteristics among Pre- and Post-menopausal Women in a Population-Based Case–Control Study from Poland

Autocrine Prolactin Stimulates Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to Chemotherapy

Prolactin regulates RANKL expression via signal transducer and activator of transcription 5a signaling in mammary epithelial cells of dairy cows.

A Novel Mechanism of hPRL-G129R, a Prolactin Antagonist, Inhibits Human Breast Cancer Cell Proliferation and Migration

Cebpd Suppresses Prolactin Expression and Prolactinoma Cell Proliferation

The Prolactin Receptor Mediates Hoxa1-Stimulated Oncogenicity in Mammary Carcinoma Cells

Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma.

TRPS1 Regulates the Opposite Effect of Progesterone Via RANKL in Endometrial Carcinoma and Breast Carcinoma

STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential

Abstract 3971: Progesterone impacts regulatory T cell activity to promote immunosuppression in the mammary gland

Establishing a relationship between prolactin and altered fatty acid β-Oxidation via carnitine palmitoyl transferase 1 in breast cancer cells

High expression of prolactin receptor is associated with cell survival in cervical cancer cells

Prolactin promotes growth of a spontaneous T cell lymphoma: role of tumor and host derived cytokines

High Levels of Progesterone Receptor B in MCF-7 Cells Enable Radical Anti-Tumoral and Anti-Estrogenic Effect of Progestin

Progesterone Receptor Expression as a Prognostic Factor in Luminal B Breast Cancer

Prolactin Regulates Testicular Gene Expression and Cell Cycle Processes Predominantly via JAK2/STAT5 Pathway in the Male Rat

Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death

Somatic Activating ESR1 Mutation in an Aggressive Prolactinoma